(Q37135355)

English

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

scientific article published on December 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ulcerative colitis

1 reference

based on heuristic

inferred from title

author name string

S B Hanauer

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

W J Sandborn

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

C Dallaire

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A Archambault

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

B Yacyshyn

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

C Yeh

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

N Smith-Hall

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Canadian Journal of Gastroenterology & Hepatology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

827-834

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 January 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

The epidemiology of inflammatory bowel disease in Canada: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

14 September 2017

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

14 September 2017

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

14 September 2017

Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

14 September 2017

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

14 September 2017

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

14 September 2017

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

27 June 2018

Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

27 June 2018

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

3 September 2018

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2658575

3 September 2018

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18080055

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2007/862917

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37135355&oldid=1797076563"